**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Cancelled) A medical device comprising:
an implantable structure; and
a histone deacetylase inhibitor, in therapeutic dosages, releasably affixed to the implantable structure for the treatment of restenosis following vascular injury.

2. (Cancelled) The medical device according to Claim 1, wherein the implantable structure comprises a stent.

3. (Cancelled) The medical device according to Claim 1, wherein the implantable structure comprises a stent-graft.

4. (Cancelled) The medical device according to Claim 1, wherein the histone deacetylase inhibitor comprises trichostatin A.

5. (Cancelled) The medical device according to Claim 1, further comprising a polymeric coating, the histone deacetylase inhibitor being incorporated into the polymeric coating.

6. (Currently Amended) A medical device comprising:
an implantable structure;
a histone deacetylase inhibitor, in thereapeutic dosages, releasably affixed to the implantable structure for the treatment of

restenosis following vascular injury, the histone deacetylase inhibitor being incorporated into a basecoat polymeric material;

an anti-proliferative, in therapeutic dosages, releasably affixed to the implantable structure for the treatment of restenosis following vascular injury, the anti-proliferative being incorporated into the basecoat polymeric material; and

a topcoat polymeric material affixed to the basecoat polymeric material to control the elution rate of the histone deacetylase inhibitor and the antiproliferative, the topcoat polymeric material and the basecoat polymeric material being immiscible polymeric materials, wherein the basecoat polymeric material includes a sixty/forty weight ratio of VDF:HFP and the topcoat comprises a four hundred ninety microgram BMA layer.

7. (Original) The medical device according to Claim 6, wherein the implantable structure comprises a stent.

8. (Original) The medical device according to Claim 6, wherein the implantable structure comprises a stent-graft.

9. (Original) The medical device according to Claim 6, wherein the histone deacetylase inhibitor comprises trichostatin A.

10. (Original) The medical device according to Claim 9, wherein the anti-proliferative comprises rapamycin.

11. (Cancelled) The medical device according to Claim 10, further comprising a polymeric coating, the histone deacetylase inhibitor and the anti-proliferative being incorporated into the polymeric coating.

12. (Cancelled) A medical device comprising:

a delivery structure; and

a histone deacetylase inhibitor, in therapeutic dosages, operatively associated with the delivery structure for the treatment of restenosis following vascular injury.

13. (Cancelled) A medical device comprising:

a delivery structure;

a histone deacetylase inhibitor, in thereapeutic dosages, operatively associated with the delivery structure for the treatment of restenosis following vascular injury; and

an anti-proliferative, in therapeutic dosages, operatively associated with the delivery structure for the treatment of restenosis following vascular injury.

14. (Cancelled) A method for treating restenosis comprising the local administration of a therapeutic dose of a histone deacetylase inhibitor.